
|Videos|December 16, 2022
The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel
Author(s)Neal Shore, MD, FACS
Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
2
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
3
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
4
John Sfakianos, MD, on moving immunotherapy earlier in NMIBC treatment pathway
5




















